Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 73 to 79 of 79 entries
Sorted by: Best Match Show Resources per page
AIMECS 99--AFMC International Medicinal Chemistry Symposium. 12-15 September 1999, Beijing, China.

IDrugs : the investigational drugs journal

Kim YH.
PMID: 16113956
IDrugs. 1999 Dec;2(12):1278-80.

The Third International Symposium of the Asian Federation for Medicinal Chemistry (AFMC) was held in Beijing from 12 to 15 September 1999. The conference covered pharmacology, molecular biology, medicinal chemistry, computational molecular modeling, biochemistry and organic synthesis. Anticancer therapies,...

Cite
Kim YH. AIMECS 99--AFMC International Medicinal Chemistry Symposium. 12-15 September 1999, Beijing, China. IDrugs. 1999;2(12):1278-80
Kim, Y. H. (1999). AIMECS 99--AFMC International Medicinal Chemistry Symposium. 12-15 September 1999, Beijing, China. IDrugs : the investigational drugs journal, 2(12), 1278-80.
Kim, Y H. "AIMECS 99--AFMC International Medicinal Chemistry Symposium. 12-15 September 1999, Beijing, China." IDrugs : the investigational drugs journal vol. 2,12 (1999): 1278-80.
Kim YH. AIMECS 99--AFMC International Medicinal Chemistry Symposium. 12-15 September 1999, Beijing, China. IDrugs. 1999 Dec;2(12):1278-80. PMID: 16113956.
Copy Download .nbib Format: NLM
The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.

OncoTargets and therapy

Meier-Stephenson V, Riemer J, Narendran A.
PMID: 28553123
Onco Targets Ther. 2017 May 16;10:2581-2593. doi: 10.2147/OTT.S136484. eCollection 2017.

PURPOSE: Refractory pediatric leukemia remains one of the leading causes of death in children. Intensification of current chemotherapy regimens to improve the outcome in these children is often limited by the effects of drug resistance and cumulative toxicity. Hence,...

Cite
Meier-Stephenson V, Riemer J, Narendran A. The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia. Onco Targets Ther. 2017;10:2581-2593doi: 10.2147/OTT.S136484.
Meier-Stephenson, V., Riemer, J., & Narendran, A. (2017). The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia. OncoTargets and therapy, 102581-2593. https://doi.org/10.2147/OTT.S136484
Meier-Stephenson, Vanessa, et al. "The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia." OncoTargets and therapy vol. 10 (2017): 2581-2593. doi: https://doi.org/10.2147/OTT.S136484
Meier-Stephenson V, Riemer J, Narendran A. The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia. Onco Targets Ther. 2017 May 16;10:2581-2593. doi: 10.2147/OTT.S136484. eCollection 2017. PMID: 28553123; PMCID: PMC5440076.
Copy Download .nbib Format: NLM
Syntheses of FDA Approved HIV Protease Inhibitors.

Synthesis

Ghosh AK, Bilcer G, Schiltz G.
PMID: 30393404
Synthesis (Stuttg). 2001;2001(15):2203-2229. doi: 10.1055/s-2001-18434.

The treatment of HIV and AIDS was revolutionized by the introduction of peptidomimetic aspartyl protease inhibitors. One of the major limitations of this type of therapy is that higher therapeutic doses are necessary because of the presence of 'peptide-like'...

Cite
Ghosh AK, Bilcer G, Schiltz G. Syntheses of FDA Approved HIV Protease Inhibitors. Synthesis (Stuttg). 2001;2001(15):2203-2229doi: 10.1055/s-2001-18434.
Ghosh, A. K., Bilcer, G., & Schiltz, G. (2001). Syntheses of FDA Approved HIV Protease Inhibitors. Synthesis, 2001(15), 2203-2229. https://doi.org/10.1055/s-2001-18434
Ghosh, Arun K, et al. "Syntheses of FDA Approved HIV Protease Inhibitors." Synthesis vol. 2001,15 (2001): 2203-2229. doi: https://doi.org/10.1055/s-2001-18434
Ghosh AK, Bilcer G, Schiltz G. Syntheses of FDA Approved HIV Protease Inhibitors. Synthesis (Stuttg). 2001;2001(15):2203-2229. doi: 10.1055/s-2001-18434. PMID: 30393404; PMCID: PMC6211199.
Copy Download .nbib Format: NLM
HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Frontiers in pharmacology

Kajogoo VD, Gorret Atim M, Amare D, Geleta M, Muchie Y, Tesfahunei HA, Olomi W, Acam J, Manyazewal T.
PMID: 34790115
Front Pharmacol. 2021 Nov 01;12:635089. doi: 10.3389/fphar.2021.635089. eCollection 2021.

No abstract available.

Cite
Kajogoo VD, Gorret Atim M, Amare D, et al. HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2021;12:635089doi: 10.3389/fphar.2021.635089.
Kajogoo, V. D., Gorret Atim, M., Amare, D., Geleta, M., Muchie, Y., Tesfahunei, H. A., Olomi, W., Acam, J., & Manyazewal, T. (2021). HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in pharmacology, 12635089. https://doi.org/10.3389/fphar.2021.635089
Kajogoo, Violet Dismas, et al. "HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Frontiers in pharmacology vol. 12 (2021): 635089. doi: https://doi.org/10.3389/fphar.2021.635089
Kajogoo VD, Gorret Atim M, Amare D, Geleta M, Muchie Y, Tesfahunei HA, Olomi W, Acam J, Manyazewal T. HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2021 Nov 01;12:635089. doi: 10.3389/fphar.2021.635089. eCollection 2021. PMID: 34790115; PMCID: PMC8591121.
Copy Download .nbib Format: NLM
Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy.

Current opinion in HIV and AIDS

Hammond E, Nolan D.
PMID: 19372899
Curr Opin HIV AIDS. 2007 Jul;2(4):274-81. doi: 10.1097/COH.0b013e3281c10df7.

PURPOSE OF REVIEW: Adipose tissue pathology plays a central role in lipodystrophy. This review discusses the mechanisms by which adipose tissue responses to specific antiretroviral therapy determine clinical outcomes, and key recent data are examined that can inform the...

Cite
Hammond E, Nolan D. Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy. Curr Opin HIV AIDS. 2007;2(4):274-81doi: 10.1097/COH.0b013e3281c10df7.
Hammond, E., & Nolan, D. (2007). Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy. Current opinion in HIV and AIDS, 2(4), 274-81. https://doi.org/10.1097/COH.0b013e3281c10df7
Hammond, Emma, and Nolan, David. "Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy." Current opinion in HIV and AIDS vol. 2,4 (2007): 274-81. doi: https://doi.org/10.1097/COH.0b013e3281c10df7
Hammond E, Nolan D. Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy. Curr Opin HIV AIDS. 2007 Jul;2(4):274-81. doi: 10.1097/COH.0b013e3281c10df7. PMID: 19372899.
Copy Download .nbib Format: NLM
Approaches to the design of HIV protease inhibitors with improved resistance profiles.

Current opinion in HIV and AIDS

Gulnik SV, Eissenstat M.
PMID: 19373035
Curr Opin HIV AIDS. 2008 Nov;3(6):633-41. doi: 10.1097/COH.0b013e328313911d.

PURPOSE OF REVIEW: This review describes current approaches to HIV protease inhibitor design, with a focus on improving their profile against drug-resistant mutants. Potential explanations for the flat resistance profile of some potent protease inhibitors and discrepancies between the...

Cite
Gulnik SV, Eissenstat M. Approaches to the design of HIV protease inhibitors with improved resistance profiles. Curr Opin HIV AIDS. 2008;3(6):633-41doi: 10.1097/COH.0b013e328313911d.
Gulnik, S. V., & Eissenstat, M. (2008). Approaches to the design of HIV protease inhibitors with improved resistance profiles. Current opinion in HIV and AIDS, 3(6), 633-41. https://doi.org/10.1097/COH.0b013e328313911d
Gulnik, Sergei V, and Eissenstat, Michael. "Approaches to the design of HIV protease inhibitors with improved resistance profiles." Current opinion in HIV and AIDS vol. 3,6 (2008): 633-41. doi: https://doi.org/10.1097/COH.0b013e328313911d
Gulnik SV, Eissenstat M. Approaches to the design of HIV protease inhibitors with improved resistance profiles. Curr Opin HIV AIDS. 2008 Nov;3(6):633-41. doi: 10.1097/COH.0b013e328313911d. PMID: 19373035.
Copy Download .nbib Format: NLM
Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design.

Molecules (Basel, Switzerland)

Yu W, Wu X, Zhao Y, Chen C, Yang Z, Zhang X, Ren J, Wang Y, Wu C, Li C, Chen R, Wang X, Zheng W, Liao H, Yuan X.
PMID: 34885967
Molecules. 2021 Dec 05;26(23). doi: 10.3390/molecules26237385.

SARS-CoV-2 is highly homologous to SARS-CoV. To date, the main protease (Mpro) of SARS-CoV-2 is regarded as an important drug target for the treatment of Coronavirus Disease 2019 (COVID-19). Some experiments confirmed that several HIV protease inhibitors present the...

Cite
Yu W, Wu X, Zhao Y, et al. Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules. 2021;26(23)doi: 10.3390/molecules26237385.
Yu, W., Wu, X., Zhao, Y., Chen, C., Yang, Z., Zhang, X., Ren, J., Wang, Y., Wu, C., Li, C., Chen, R., Wang, X., Zheng, W., Liao, H., & Yuan, X. (2021). Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules (Basel, Switzerland), 26(23), . https://doi.org/10.3390/molecules26237385
Yu, Wei, et al. "Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design." Molecules (Basel, Switzerland) vol. 26,23 (2021). doi: https://doi.org/10.3390/molecules26237385
Yu W, Wu X, Zhao Y, Chen C, Yang Z, Zhang X, Ren J, Wang Y, Wu C, Li C, Chen R, Wang X, Zheng W, Liao H, Yuan X. Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules. 2021 Dec 05;26(23). doi: 10.3390/molecules26237385. PMID: 34885967; PMCID: PMC8659229.
Copy Download .nbib Format: NLM
Showing 73 to 79 of 79 entries